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The bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway is a central regula-
tor of hepcidin expression and systemic iron balance. However, the molecular mechanisms
by which iron is sensed to regulate BMP6-SMAD signaling and hepcidin expression are
unknown. Here we examined the effects of circulating and tissue iron on Bmp6-Smad
pathway activation and hepcidin expression in vivo after acute and chronic enteral iron
administration in mice. We demonstrated that both transferrin saturation and liver iron
content independently inﬂuence hepcidin expression. Although liver iron content is inde-
pendently positively correlated with hepatic Bmp6 messenger RNA (mRNA) expression
and overall activation of the Smad1/5/8 signaling pathway, transferrin saturation activates
the downstream Smad1/5/8 signaling cascade, but does not induce Bmp6 mRNA expres-
sion in the liver. Hepatic inhibitory Smad7 mRNA expression is increased by both acute
and chronic iron administration and mirrors overall activation of the Smad1/5/8 signaling
cascade. In contrast to the Smad pathway, the extracellular signal-regulated kinase 1 and 2
(Erk1/2) mitogen-activated protein kinase (Mapk) signaling pathway in the liver is not
activated by acute or chronic iron administration in mice. Conclusion: Our data demon-
strate that the hepatic Bmp6-Smad signaling pathway is differentially activated by circulat-
ing and tissue iron to induce hepcidin expression, whereas the hepatic Erk1/2 signaling
pathway is not activated by iron in vivo. (HEPATOLOGY 2011;54:273-284)
See Editorial on Page 16
T
he liver hormone hepcidin is a main regulator
of systemic iron homeostasis (reviewed in 1).
Hepcidin binds and induces degradation of fer-
roportin, an iron exporter expressed on the surface of
duodenal enterocytes, reticuloendothelial macrophages,
and hepatocytes.2 Hepcidin-mediated ferroportin degra-
dation limits iron release from these cells to the blood-
stream, thereby reducing iron absorption from the diet
and iron mobilization from body stores. Hepcidin deﬁ-
ciency and unregulated ferroportin activity are the com-
mon pathogenic mechanism for the iron overload disor-
der hereditary hemochromatosis due to mutations in the
genes encoding hepcidin itself (HAMP), hemojuvelin
(HFE2), the hemochromatosis protein HFE, and
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transferrin receptor 2 (TFR2), whereas hepcidin excess
contributes to the anemia of chronic disease (reviewed1).
A number of stimuli modulate hepcidin expression
to inﬂuence systemic iron balance. Erythropoietic
demand and hypoxia down-regulate hepcidin transcrip-
tion to increase iron availability, whereas iron, inﬂam-
matory cytokines, and endoplasmic reticulum stress
up-regulate hepcidin transcription to decrease iron avail-
ability.1,3-7 The speciﬁc signaling pathways mediating
hepcidin transcription in response to these stimuli are
increasingly being elucidated. Inﬂammatory cytokines
stimulate hepcidin transcription by way of the signal
transducer and activator of transcription 3 (STAT3) sig-
naling pathway, whereas iron stimulates hepcidin tran-
scription by way of the bone morphogenetic protein
(BMP)-SMAD signaling pathway (reviewed1).
BMPs belong to the transforming growth factor-
beta (TGF-b) superfamily of ligands and are involved
in a myriad of cellular and systemic functions during
embryonic and adult life (reviewed8). BMPs form a sig-
naling complex with type I and type II serine threonine
kinase receptors, leading to phosphorylation of intracellu-
lar SMAD1, SMAD5, and SMAD8 proteins. These
P-SMAD1/5/8 proteins form a complex with SMAD4
and translocate to the nucleus to modulate transcription
of target genes such as ID1 and SMAD7.9,10 Hepcidin is
also a target transcript directly up-regulated by the BMP
signaling pathway (reviewed in 1). The central impor-
tance of the BMP-SMAD signaling pathway in hepcidin
regulation and iron metabolism in vivo is demonstrated
by the fact that mutations in the genes encoding the
BMP coreceptor hemojuvelin,11,12 the intracellular signal-
ing molecule SMAD4,13 and the ligand BMP69,14 each
result in decreased hepcidin expression and iron overload.
Furthermore, pharmacologic modulators of the BMP-
SMAD signaling pathway regulate hepcidin expression
and systemic iron balance in mice.9,15,16
Notably, the molecular mechanisms by which iron
is sensed to induce the BMP-SMAD pathway are not
fully understood. Both circulating and tissue iron have
been suggested to regulate hepcidin expression.
Whether they exert independent effects through the
BMP-SMAD pathway and/or involve additional path-
ways is unclear. For example, although liver iron con-
tent (LIC) is correlated with hepatic Bmp6 messenger
RNA (mRNA) levels in mice,17-19 suggesting that tis-
sue iron levels regulate BMP-SMAD pathway activity
by regulating ligand expression, it is unknown whether
circulating iron levels also regulate hepatic BMP6
mRNA, or whether circulating iron sensitizes hepato-
cytes to increase SMAD1/5/8 phosphorylation in
response to tonic BMP6 levels. Additionally, although
recent studies suggest that HFE and possibly TFR2
may regulate hepcidin expression through an interac-
tion with the BMP6-SMAD signaling pathway,18,20-24
several studies provide indirect evidence suggesting that
hepatic MAPK signaling, more speciﬁcally the ERK1/2
kinases, may also be involved in hepcidin regulation by
iron mediated by TFR2 and/or HFE.21,25-27 Notably,
crosstalk between the canonical SMAD signaling path-
way and the MAPK pathway is well described
(reviewed28). However, the physiologic relevance of the
ERK/MAPK signaling pathway in iron homeostasis in
vivo is still unknown.
Recent studies suggest a role for inhibitory SMAD7
in hepcidin regulation and iron homeostasis.10,17,23,24
Inhibitory SMADs function as feedback inhibitors of
the BMP/TGF-b pathway by interacting with type I
receptors to block their phosphorylation or to promote
receptor dephosphorylation or degradation.8 Hepatic
Smad7 mRNA is induced by chronic dietary iron load-
ing in mice concordantly with hepcidin and Id1
mRNA,17 and SMAD7 was recently shown to be a
speciﬁc inhibitor of hepcidin transcription in vitro.10
Alterations in hepatic SMAD7 mRNA expression have
also been found in hemochromatosis patients.23,24
However, the physiologic signiﬁcance and timing of
SMAD7 activation upon iron administration in vivo
need further evaluation.
Here we investigated the molecular mechanisms by
which iron is sensed to regulate BMP6-SMAD signal-
ing and hepcidin expression. We performed a detailed
time course of both acute and chronic enteral iron
administration in mice to obtain different conditions
of body iron perturbation including isolated increases
of either transferrin saturation (Tf sat) or LIC. Then
we dissected the BMP6-SMAD signaling pathway from
the induction of tissue-speciﬁc Bmp6 ligand mRNA
expression, to the activation of intracellular signal medi-
ators including P-Smad1/5/8 and Erk1/2 proteins, to
the modulation of target transcript expression including
hepcidin (Hamp, also known as Hamp1), Id1, and
Smad7. Our aim was to determine how tissue and cir-
culating iron stimulate the Bmp6-Smad signaling path-
way to regulate hepcidin expression, and whether the
Erk1/2 pathway is stimulated by iron.
Materials and Methods
Animals. All animal protocols were approved by the
Institutional Animal Care and Use Committee at the
Massachusetts General Hospital and used C57Bl/6
male mice. For chronic iron administration experi-
ments, 7-week-old mice were sacriﬁced at time zero
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(Baseline) or received a high iron diet (2% carbonyl
iron, TD.08496, Harlan Teklad) for 24 hours to 3
weeks prior to sacriﬁce (n ¼ 6 per group). A separate
cohort of 7-week-old mice were sacriﬁced at time zero
(Baseline), received a high iron diet for 1 week, or
received a high iron diet for 1 week followed by a low
iron diet (2-6 ppm iron, TD.80396, Harlan Teklad)
for 24 hours to 8 days prior to sacriﬁce (n ¼ 4 per
group). For acute iron administration experiments,
9-week-old mice were sacriﬁced at time zero (Baseline)
or received 2 mg of elemental iron per kg mouse
weight as iron sulfate (Elixir, CVS) in 100 lL distilled
water (Iron groups) or 100 lL distilled water alone
(Mock groups) by oral gavage 1 to 24 hours prior to
sacriﬁce (n ¼ 6 per group). To better detect the effects
of iron administration for both acute and chronic
experiments, mice received a low iron diet for 12-14
days prior to iron administration because this regimen
has been reported previously to circumvent the hepci-
din stimulation induced by the high iron content of
usual rodent diets without inducing hypoferremia6
(Supporting Fig. 1, Supporting Table 1).
Hematologic and Iron Analysis. Complete blood
count (CBC), serum iron, Tf sat, and liver and spleen
nonheme iron concentrations were measured as previ-
ously described.15,22
Quantitative Real-Time Reverse-Transcription Po-
lymerase Chain Reaction (RT-PCR). Total RNA was
isolated from liver and Bmp6, Hamp, Id1, and Smad7
relative to Rpl19 mRNA levels were measured using two-
step quantitative real-time RT-PCR as described.9,10,18
Western Blot. Liver lysates were generated and western
blot for P-Smad1/5/8 relative to Smad1 was performed
essentially as described.18,22 Western blot for phosphoryl-
ated Erk1/2 (P-Erk1/2) relative to total Erk1/2 was per-
formed according to the manufacturer’s instructions using
phospho-p44/42 MAPK (P-Erk1/2, diluted 1:1,000) and
p44/42 MAPK (Erk1/2, diluted 1:5,000) rabbit polyclonal
antibodies (Cell Signaling Technology). Chemilumines-
cence was quantiﬁed as described.15
Statistics. Statistical signiﬁcance was determined by
one-way or two-way analysis of variance (ANOVA) with
the Holm-Sidak or the Dunnett’s post-hoc tests for pair-
wise multiple comparisons as indicated. For small sample
sizes, we used the Spearman rho test to assess the correla-
tions between continuous variables. Simple and multivar-
iate linear regression analysis was performed to identify
the best explanatory variables for Hamp and Bmp6
mRNA levels. Statistical analyses were conducted using
SPSS v. 18.0 (Chicago, IL) and SigmaStat v. 3.5 (Systat
Software, Richmond, CA) statistical software, and P <
0.05 was considered signiﬁcant.
Results
Hepcidin Is Independently Positively Correlated
with Both Tf sat and LIC. To further dissect how
iron is sensed to modulate hepcidin expression, we
treated mice with a single dose of iron by oral gavage
(acute iron treatment), with a high iron diet (chronic
iron treatment), or with a high iron diet followed by a
low iron diet in order to achieve different conditions
of body iron perturbation, including isolated increases
of either Tf sat or LIC.
In the chronic iron treatment experiment, serum
iron (Fig. 1A), Tf sat (Fig. 1B), and LIC (Fig. 1C) all
signiﬁcantly increased by 24 hours. However, whereas
serum iron and Tf sat plateaued for the subsequent 3
weeks, LIC continued to progressively increase. Thus,
we achieved a condition of increasing LIC in the face of
stable (albeit high) circulating iron levels. In the chronic
iron treatment setting, hepatic Hamp mRNA expression
signiﬁcantly and progressively increased between baseline
and 48 hours, and then plateaued for the remaining 3
weeks (Fig. 1D). Although both LIC and Tf sat posi-
tively correlated with Hamp mRNA levels (r ¼ 0.456,
P ¼ 0.002; r ¼ 0.658, P < 0.001, respectively) and sig-
niﬁcantly inﬂuenced Hamp mRNA expression by simple
linear regression analysis (R2 ¼ 0.21, b ¼ 0.456, P ¼
0.002; R2 ¼ 0.43, b ¼ 0.658, P < 0.001, respectively)
by multivariate analysis, Tf sat was the only independent
predictor of hepatic Hamp mRNA levels (R2 ¼ 0.46,
b ¼ 0.57, P < 0.001) in this setting.
Although the inﬂuence of LIC on Hamp mRNA
levels was difﬁcult to detect in the chronic iron treat-
ment setting where both LIC and Tf sat were elevated,
mice switched to a low iron diet after receiving a high
iron diet for 1 week maintained a high LIC for up 8
days (Fig. 2C), whereas serum iron and Tf sat
decreased back to baseline levels by 24-48 hours (Fig.
2A,B), allowing us to examine the effects of an isolated
elevated LIC with normal circulating iron levels. The
low iron diet signiﬁcantly decreased hepatic Hamp
mRNA levels from those achieved by 1 week of a high
iron diet within 24 hours and for up to 8 days (Fig.
2D), reﬂecting the decrease in serum iron and Tf sat,
and consistent with a role for circulating iron in regu-
lating hepcidin expression. Notably, Hamp mRNA lev-
els remained signiﬁcantly elevated above baseline for
up to 8 days in these mice, suggesting an independent
role for LIC in inducing hepcidin expression. Indeed,
by multivariate analysis, both Tf sat and LIC were in-
dependent predictors of hepatic Hamp mRNA levels
in this model (R2 ¼ 0.856; b ¼ 0.004, P < 0.001 for
Tf sat; b ¼ 0.0004, P < 0.001 for LIC).
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In the acute iron treatment experiment, both serum
iron (Fig. 3A) and Tf sat (Fig. 3B) were signiﬁcantly
increased by a single dose of 2 mg/kg iron at 1 and 4
hours after oral gavage (black bars) compared with
untreated animals (Baseline) or with mock gavage (gray
bars), with a return to baseline by 8-24 hours. In con-
trast, LIC was unchanged at all timepoints in comparison
to baseline and the respective mock groups (Fig. 3C).
In the acute iron treatment experiment, hepatic
Hamp mRNA showed a progressive temporal increase,
and was signiﬁcantly increased at 4 and 8 hours after
iron gavage in comparison to baseline and the corre-
sponding mock groups, with a return to baseline levels
by 24 hours (Fig. 3D, black bars). The mock group
did not manifest signiﬁcant differences in Hamp
mRNA compared to baseline, although there was a
trend toward a higher value at 4 hours after mock ga-
vage, suggesting a possible effect of the gavage procedure
itself in a few animals (Fig. 3D, gray bars). In the iron
group, hepatic Hamp mRNA was correlated with Tf
sat (r ¼ 0.455, P ¼ 0.012), but not LIC (r ¼ 0.193,
P ¼ 0.307), which was in fact not changed. By multi-
variate analysis, Tf sat was the only independent predic-
tor of Hamp mRNA levels (R2 ¼ 0.23, b ¼ 0.444,
Fig. 1. Chronic dietary iron administration increases serum iron, serum transferrin saturation, liver iron content, and hepatic hepcidin mRNA in
mice. Seven-week-old male C57BL/6 mice were placed on a high iron diet (2% carbonyl iron) and were sacriﬁced at time zero (Baseline), 24
hours, 48 hours, 72 hours, 1 week, 2 weeks, or 3 weeks after initiation of the high iron diet (n ¼ 6 per group). Animals were analyzed for se-
rum iron (A), Tf sat (B), LIC (C), and hepcidin (Hamp, also known as Hamp1) relative to Rpl19 mRNA expression by quantitative real-time RT-
PCR (D). Results are expressed as the mean 6 SD for serum and tissue iron parameters, and as the mean 6 SD for the fold change compared
to the baseline for hepcidin expression. Statistical signiﬁcance was determined by one-way ANOVA with Holm-Sidak or the Dunnett’s post-hoc
tests for pairwise multiple comparisons. A high iron diet signiﬁcantly increased serum iron (A, F ¼ 10.16, P < 0.001), Tf sat (B, F ¼ 65.79, P
< 0.001), LIC (C, F ¼ 172.32, P < 0.001), and Hamp relative to Rpl19 mRNA (D, F ¼ 99.40, P < 0.001). For each group signiﬁcant
changes are shown as (*) P < 0.001 in comparison with the baseline, and (&) for P < 0.001 or as otherwise indicated if signiﬁcant in com-
parison with the previous group.
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and P < 0.001). These data provide further evidence
that Tf sat independently regulates hepatic Hamp
mRNA expression.
Hepatic Bmp6 mRNA Is Independently Positively
Correlated with LIC, but Not Tf sat. Next, we inves-
tigated the role of the BMP6-SMAD signaling path-
way in hepcidin induction by acute and chronic iron
administration. Similar to prior studies,17,18 chronic
iron treatment signiﬁcantly increased hepatic Bmp6
mRNA levels in comparison to the baseline group,
with a temporal progressive increase similar to LIC
(compare Figs. 4A and 1C). Although one prior study
suggested that the small intestine may also be a source
of BMP6 in response to iron,29 we did not see any
effects of chronic iron treatment on Bmp6 mRNA
expression in either the duodenum (Supporting Fig. 2),
in agreement with other studies,19,30 or the spleen,
another key iron homeostasis organ (Supporting Fig. 3).
The Spearman’s rho test conﬁrmed a strong correlation
between hepatic Bmp6 mRNA levels and LIC (r ¼
0.902, P < 0.001), and multivariate regression analysis
demonstrated that LIC was the only factor associated
Fig. 2. Hamp mRNA levels are independently inﬂuenced by both LIC and Tf sat. Seven-week-old male C57BL/6 mice received a standard
rodent diet (Baseline), a high iron diet for 1 week (High Fe), or a high iron diet for 1 week followed by a low iron diet (2-6 ppm iron; High Fe
then Low Fe) for 24 hours to 8 days as indicated (n ¼ 4 per group). Tissues were analyzed for serum iron (A), Tf sat (B), LIC (C), and Hamp rel-
ative to Rpl19 mRNA by quantitative real-time RT-PCR (D). Results are expressed as the mean 6 SD. Statistical signiﬁcance was determined by
one-way ANOVA with Holm-Sidak or the Dunnett’s post-hoc tests for pairwise multiple comparisons. For each group, *P < 0.001 or as otherwise
indicated if signiﬁcant in comparison to Baseline, #P < 0.001 or as otherwise indicated if signiﬁcant in comparison with the High Fe group. A
high iron diet signiﬁcantly increased serum iron, Tf sat, LIC, and Hamp relative to Rpl19 mRNA relative to baseline (A-D). After switching to a
low iron diet for 24 hours to 8 days, serum iron and Tf sat were signiﬁcantly decreased back to baseline levels for all timepoints, except 8 days,
where there was a small but signiﬁcant reduction in Tf sat from baseline (A,B). After switching to a low iron diet for 24 hours to 8 days, a signif-
icantly increased LIC was maintained compared with the baseline group, and the LIC was not signiﬁcantly decreased from the High Fe group,
except for a small but signiﬁcant decrease at 24 hours (C). After switching to a low iron diet for 24 hours to 8 days, Hamp relative to Rpl19
mRNA levels were decreased to an intermediate level between those achieved by the high iron diet and baseline (D).
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with hepatic Bmp6 mRNA levels, independent of Tf
sat, serum iron, hemoglobin, and mean cellular hemo-
globin concentration (R2 ¼ 0.846, b ¼ 1.032, P <
0.001). These data suggest that LIC may have a role
in hepatic Bmp6 induction by iron.
In contrast, hepatic Bmp6 mRNA was not signiﬁ-
cantly increased by acute iron administration (Fig. 4B,
black bars), where Tf sat increased but LIC did not
change. The mock groups (Fig. 4B, gray bars) did
show a small but signiﬁcantly lower Bmp6 expression
at 1 and 24 hours after gavage in comparison to the
baseline group, and at 1 and 4 hours after gavage in
comparison to the corresponding iron timepoints;
however, the overall trend of both iron and mock
groups were similar, possibly reﬂecting an effect from
the gavage itself or circadian ﬂuctuations of hepatic
Bmp6 mRNA. Importantly, we did not ﬁnd any corre-
lation between Tf sat and hepatic Bmp6 mRNA levels
(r ¼ 0.237, P ¼ 0.068). Additionally, we did not see
a corresponding decrease in hepatic Smad1/5/8 phos-
phorylation or Bmp6-Smad target gene expression by
mock gavage (see Figs. 5B, 6C,D, gray bars), suggest-
ing that this small decrease in Bmp6 expression in the
mock group was not functionally relevant. We also did
Fig. 3. Acute enteral iron administration increases serum iron and Tf sat, but not LIC, and induces hepatic Hamp mRNA expression in mice.
Nine-week-old male C57BL/6 mice received a single dose of 2 mg elemental iron per kg animal weight (Iron, black bars) or the same volume
of water alone by oral gavage (Mock, gray bars). Mice were sacriﬁced at time 0 (without any treatment, Baseline), and at 1, 4, 8, and 24 hours
after either iron or water gavage (n ¼ 6 per group). Animals were analyzed for serum iron (A), Tf sat (B), LIC (C), and Hamp relative to Rpl19
mRNA expression by quantitative real-time RT-PCR (D). Results are expressed as the mean 6 SD for serum and tissue iron parameters, and as
the mean 6 SD for the fold change compared to the baseline for hepcidin expression. Statistical signiﬁcance was determined by two-way ANOVA
with Holm-Sidak or Dunnett’s post-hoc tests for pairwise multiple comparisons. Compared with baseline or mock gavage, a single dose of iron
by oral gavage signiﬁcantly increased serum iron (A, F ¼ 3.974, P ¼ 0.007 for time, F ¼ 25.002, P < 0.001 for treatment), serum Tf sat (B,
F ¼ 3.285, P ¼ 0.018 for time, F ¼ 21.223, P < 0.001 for treatment), and Hamp relative to Rpl19 mRNA (D, F ¼ 8.941, P ¼ 0.001 for
time, F ¼ 10.678, P ¼ 0.002 for treatment), but did not affect LIC (C, F ¼ 1.60, P ¼ 0.189 for time, F ¼ 0.936, P ¼ 0.338 for treatment).
For each iron treated group, signiﬁcant changes are shown as exact P values for the comparisons with the baseline (*), with the previous group
(&), and with the corresponding mock group (#).
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not ﬁnd signiﬁcant increases in duodenal or splenic
Bmp6 mRNA in response to acute iron administration
(Supporting Figs. 2, 3). Together, these data suggest
that Tf sat does not induce hepcidin expression by
stimulating Bmp6 mRNA expression.
Increases in LIC and Tf sat Each Stimulate
Hepatic Smad1/5/8 Signaling and Smad7 mRNA
Expression. Next, we analyzed the intracellular signal-
ing mediators and targets of BMP6 signaling
(P-Smad1/5/8 protein, Id1 mRNA, and Smad7
mRNA) in the liver after both chronic and acute iron
administration. In the chronic iron administration set-
ting, hepatic P-Smad1/5/8 protein (Fig. 5A), Id1
mRNA (Fig. 6A), and Smad7 mRNA (Fig. 6B) exhib-
ited signiﬁcant increases at nearly all timepoints in
comparison to the baseline group. The pattern of
increase reﬂected the trend of both LIC and hepatic
Bmp6 mRNA, where there was a relative plateau or
decrease in the rate of increase between 48-72 hours
and between 2-3 weeks (compare Figs. 5A, 6A,B with
Figs. 1C, 4A). These data support the hypothesis that
LIC activates the Smad1/5/8 signaling pathway
through Bmp6 ligand induction. These data also sug-
gest that hepatic Smad7 mRNA expression follows the
overall activation of the Bmp6-Smad1/5/8 pathway.
In the acute setting, mock gavage had no effect on
hepatic P-Smad1/5/8 protein, Id1 mRNA, or Smad7
mRNA expression (Figs. 5B, 6C,D, gray bars). After
acute iron administration, hepatic P-Smad1/5/8 pro-
tein showed a trend toward a temporal progressive
increase that reached its peak at 4 hours after gavage
and then decreased back to baseline (Fig. 5B).
Although the increase in hepatic P-Smad1/5/8 protein
did not achieve statistical signiﬁcance for the time vari-
able, it was signiﬁcantly increased in the iron group
compared with the corresponding mock groups at 4
and 8 hours after gavage (Fig. 5B). Reﬂecting the
increased hepatic P-Smad1/58 protein, hepatic Id1
mRNA expression exhibited signiﬁcant increases
between the iron and the corresponding mock gavage
groups as well as the baseline (Fig. 6C). Similarly,
hepatic Smad7 mRNA expression was signiﬁcantly
increased in the iron groups compared with the corre-
sponding mock groups, although there was only an
overall trend toward increased hepatic Smad7 mRNA
expression after iron gavage compared with the base-
line group (Fig. 6D). These data are consistent with
the hypothesis that increases in Tf sat activate the
Smad1/5/8 signaling cascade downstream of BMP6
ligand, and that hepatic Smad7 mRNA expression fol-
lows the overall activation of the Bmp6-Smad1/5/8
signaling pathway.
Increases in LIC and Tf sat Do Not Affect Hepatic
Erk Signaling or the Inﬂammatory Pathway. Because
it has been suggested that Erk1/2 proteins might be
involved in hepcidin regulation,21,25-27 we also meas-
ured the phosphorylation levels of these kinases in the
liver after both chronic and acute iron administration.
Fig. 4. Chronic iron administration stimulates hepatic Bmp6 mRNA expression but acute iron administration does not. The animals that under-
went chronic iron administration from Fig. 1 (A) and acute iron administration from Fig. 3 (B) were analyzed for hepatic Bmp6 relative to Rpl19
mRNA expression by quantitative real-time RT-PCR (n ¼ 6 per group). Results are expressed as the mean 6 SD for the fold change compared
to the baseline. Statistical signiﬁcance was determined by one-way ANOVA (chronic iron administration, A) or two-way ANOVA (acute iron admin-
istration, B) with Holm-Sidak or Dunnett’s post-hoc tests for pairwise multiple comparisons. For each group, signiﬁcant changes are shown as
exact P values for the comparisons with the baseline (*), with the previous group (&), and with the corresponding iron group (#). Hepatic Bmp6
relative to Rpl19 mRNA was signiﬁcantly increased from baseline by chronic iron administration (A, F ¼ 30.20, P < 0.001), but not by acute
iron administration (B), although there was a slight decrease in hepatic Bmp6 relative to Rpl19 mRNA in mock gavage groups compared to the
baseline group and the corresponding iron timepoints (B, F ¼ 4.509, P ¼ 0.003 for time, F ¼ 6.99, P ¼ 0.011 for treatment).
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In contrast to hepatic P-Smad1/5/8 protein and Id1
mRNA, P-Erk1/2 expression did not signiﬁcantly
increase after either chronic iron administration (Fig. 7A)
or acute iron gavage in comparison to the baseline or the
corresponding mock groups (Fig. 7B). In fact, there was
a temporal progressive decrease in P-Erk1/2 for both the
acute iron and mock gavage groups, possibly reﬂecting a
circadian ﬂuctuation or an effect of the gavage itself. For
both the chronic and acute iron administration experi-
ments, there was a large variability of hepatic P-Erk1/2
expression within each group, suggesting that other fac-
tors might drive phosphorylation of these MAP kinases.
Because inﬂammatory cytokines such as IL6 are also
potent stimulators of hepcidin expression,1,3-6 we exam-
ined whether chronic or acute iron administration or
the gavage procedure affected the inﬂammatory path-
way. There was no signiﬁcant stimulation of hepatic Il6
mRNA or target transcript Crp expression in the
chronic iron treatment setting or in response to acute
mock or iron gavage (Supporting Fig. 4).
Discussion
It is well known that iron overload induces hepcidin
transcription,3 and it was previously shown that hepci-
din correlates with LIC.31,32 The fact that transferrin-
bound iron might induce hepcidin expression has been
suggested in humans,6,33 and demonstrated in vitro.33
Fig. 5. Chronic and acute iron
administration both stimulate he-
patic Smad1/5/8 signaling. The
animals that underwent chronic
iron administration from Fig. 1 (A)
and acute iron administration from
Fig. 3 (B) were analyzed for he-
patic phosphorylated Smad1/5/8
(P-Smad 1-5-8) relative to Smad1
protein by western blot followed by
chemiluminescence quantitation.
Results are expressed and sta-
tistics analyzed as in Fig. 4.
Chronic iron treatment signiﬁcantly
increased hepatic P-Smad1/5/8
relative to total Smad1 protein
(A, F ¼ 21.75, P < 0.001). Simi-
larly, acute iron administration
signiﬁcantly increased hepatic
P-Smad1/5/8 relative to total
Smad1 protein compared with the
corresponding mock treatment
groups, and showed a trend toward
a temporal progressive increase
compared to baseline (B, F ¼
5.855, P ¼ 0.02 for treatment,
F ¼ 2.246, P ¼ 0.073 for time).
For each iron treated group, signiﬁ-
cant changes are shown as exact
P values for the comparisons with
the baseline (*), with the previous
group (&), and with the corre-
sponding mock group (#).
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To study the separate effects of circulating and tissue
iron on hepcidin regulation, we treated animals with
acute or chronic iron administration to obtain isolated
increases of either Tf sat or LIC. We aimed to make
the iron treatments as physiologic as possible by choos-
ing an enteral administration route and a 2 mg/kg
iron dose for gavage, the lowest effective dose to signif-
icantly increase Tf sat without affecting LIC in prelim-
inary experiments (data not shown), about equivalent
to a human patient taking two over-the-counter iron
sulfate supplement pills (65 mg elemental iron each).
Although the presence of circulating nontransferrin-
bound iron (NTBI) and its redox active form (labile
iron pool) LPI may not be excluded,34 we targeted
and achieved a submaximal Tf sat of up to 82% with
acute iron treatment and 95% with chronic iron treat-
ment. In the acute iron administration setting, where
Tf sat was increased but LIC was not, Hamp mRNA
expression was also signiﬁcantly increased. Addition-
ally, in the chronic iron administration setting, Tf sat
was an independent predictor of Hamp mRNA level
by multivariate analysis. Thus, our data clearly demon-
strate that Tf sat plays a crucial role in hepcidin regu-
lation in vivo.
The BMP-SMAD signaling pathway is a main regula-
tor of hepcidin expression and systemic iron homeostasis,1
Fig. 6. Chronic and acute iron administration both stimulate expression of hepatic Bmp6-Smad1/5/8 target transcripts Id1 and Smad7. The
animals that underwent chronic iron administration from Fig. 1 (A,B) and acute iron administration from Fig. 3 (C,D) were analyzed for hepatic
Id1 (A,C) and Smad7 (B,D) relative to Rpl19 mRNA by quantitative real-time RT-PCR. Results are expressed and statistics analyzed as in Fig. 4.
Chronic iron treatment signiﬁcantly increased hepatic Id1 (A, F ¼ 27.745, P < 0.001) and Smad7 relative to Rpl19 mRNA (B, F ¼ 7.41, P <
0.001). Acute iron administration also signiﬁcantly increased hepatic Id1 relative to Rpl19 mRNA compared with the corresponding mock treat-
ment groups and the baseline (C, F ¼ 13.676, P < 0.001 for treatment, F ¼ 4.944, P ¼ 0.002 for time). Acute iron administration also signif-
icantly increased hepatic Smad7 relative to Rpl19 mRNA compared with the corresponding mock groups, although there was only an overall
trend toward increased expression compared with the baseline group (D, F ¼ 19.208, P < 0.001 for treatment, F ¼ 1.548, P ¼ 0.203 for
time). For each iron treated group, signiﬁcant changes are shown as exact P values for the comparisons with the baseline (*), with the previous
group (&), and with the corresponding mock group (#).
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and Tf sat has been suggested to signal to hepcidin
through the BMP-SMAD pathway by indirect proofs
and in vitro.33 Here we showed that hepatic
P-Smad1/5/8 protein and Id1 mRNA were increased
in the acute iron administration setting where Tf sat
was increased but LIC and hepatic Bmp6 mRNA
were not. Thus, our data demonstrates that Tf sat
activates the BMP-SMAD signaling pathway inde-
pendently of LIC and downstream of hepatic BMP6
mRNA induction. The mechanism by which Tf sat
activates SMAD phosphorylation remains uncertain.
We did not see a clear effect of acute iron adminis-
tration on expression of the BMP coreceptor hemo-
juvelin or the serine protease TMPRSS6, which is
reported to cleave hemojuvelin35 (Supporting Fig. 5).
Interestingly, SMAD phosphorylation and BMP-
SMAD target transcript expression has been demon-
strated to be impaired relative to the degree of iron
overload and BMP6 expression in Hfe and Tfr2 null
mice and human patients with HFE mutations18,20-24
(Corradini E, Babitt JL, Fleming RE, et al., unpubl.
data), suggesting that HFE and TFR2 may be
involved. This may be one mechanism accounting
for the blunted hepcidin induction in response to an
oral iron challenge in human patients with HFE
hemochromatosis.36
Fig. 7. Chronic and acute iron
administration have no effect of
hepatic Erk1/2 phosphorylation.
The animals that underwent
chronic iron administration from
Fig. 1 (A) and acute iron adminis-
tration from Fig. 3 (B) were ana-
lyzed for hepatic phosphorylated
Erk1/2 (P-ERk1/2) relative to total
Erk1/2 protein by western blot fol-
lowed by chemiluminescence
quantitation. Results are expressed
and statistics analyzed as in Fig.
4. Chronic iron administration had
no signiﬁcant effect on hepatic
P-Erk1/2 relative to total Erk1/2
(A, F ¼ 0.761, P ¼ 0.608). Acute
iron administration had no signiﬁ-
cant effect on hepatic P-Erk1/2
relative to total Erk1/2 compared
with the corresponding mock ga-
vage groups, although there was a
temporal progressive decrease in
hepatic P-Erk1/2 relative to Erk1/
2 in both the iron and mock ga-
vage groups (B,F ¼ 2.246, P ¼
0.142 for treatment, F ¼ 5.188,
P ¼ 0.002 for time). For each
iron-treated group, signiﬁcant
changes are shown as exact P val-
ues for the comparisons with the
baseline (*), with the previous
group (&), and with the corre-
sponding mock group (#).
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LIC was also found to be an independent factor
predictive of hepatic Hamp mRNA levels by multivari-
ate analysis in the setting of an isolated elevated LIC
with normal circulating iron levels. In the chronic iron
treatment setting, LIC was strongly and independently
associated with increases in hepatic Bmp6 mRNA
expression, a main stimulator of hepcidin expres-
sion,9,14 similar to published studies.17-19 These data
suggest that the mechanism by which LIC stimulates
hepcidin expression is by stimulating Bmp6 mRNA
expression, thereby activating the SMAD signaling
pathway. Indeed, whereas 1 week of a high iron diet
increased Hamp mRNA levels 10-fold above baseline,
coadministration of a neutralizing anti-BMP6 antibody
(which we have demonstrated speciﬁcally blocks
BMP6-SMAD signaling9) with the high iron diet
blocked the Hamp mRNA increase, resulting in
increased liver iron deposition (Supporting Fig. 6).
These data are consistent with the phenotype of Bmp6
null mice, which exhibit decreased hepatic nuclear
P-Smad1/5/8 expression, hepcidin deﬁciency, and iron
overload.9,14
Interestingly, we did not detect an independent
effect of LIC on Hamp mRNA expression in the
chronic iron treatment setting. Indeed, although Hamp
mRNA was increased over 24-48 hours on a high iron
diet in the setting of increases in both Tf sat and LIC,
Hamp subsequently plateaued over the next 3 weeks
despite continued increases in LIC. LIC may have
more of an apparent effect on hepcidin regulation
under conditions where Tf sat is not elevated. It is also
possible that this plateau in hepatic Hamp mRNA lev-
els was due to competing inﬂuences of stimulation by
Bmp6 and feedback inhibition, for example, through
inhibitory Smad7 that was also increased in this set-
ting. Indeed, Smad7 has been shown to inhibit hepci-
din transcription in vitro.10 Interestingly, in contrast to
hepcidin, other Bmp6-Smad pathway target transcripts
such as Id1 continued to increase after 48 hours on a
high iron diet along with progressive increases in LIC
and Bmp6 mRNA. This suggests that Smad7 may
have a preferential inhibitory role on hepcidin expres-
sion compared with other Bmp6-Smad target genes, or
that there are other mechanisms involved in the nega-
tive feedback of hepcidin expression that do not
involve the BMP-SMAD pathway. Further studies will
be needed to more deﬁnitively determine the role of
inhibitory Smad7 in hepcidin regulation in vivo.
In addition to the BMP-SMAD pathway, the
ERK1/2 MAP kinase signaling pathway has also been
suggested to be involved in iron homeostasis. In partic-
ular, holotransferrin, by way of TFR2 and possibly
HFE, induces the ERK1/2 cascade in vitro, and he-
patic P-Erk1/2 is reduced in Hfe, Tfr2, and Hfe-Tfr2
null mice.21,25-27 Here we demonstrated that, whereas
both chronic and acute iron treatment in mice induced
hepatic P-Smad1/5/8, Bmp-Smad target transcripts,
and Hamp mRNA, neither chronic nor acute iron
treatment induced a signiﬁcant increase in hepatic
P-Erk1/2, supporting a role for the BMP-SMAD path-
way, but not the ERK1/2 pathway, in hepcidin regula-
tion by iron in vivo. Our data also suggest that the
inﬂammatory pathway is not involved in hepcidin reg-
ulation by iron.
In summary, our results demonstrate that circulating
iron and tissue iron differentially activate the BMP-
SMAD signaling pathway to modulate hepcidin
expression. The liver is the predominant source of the
BMP6 that regulates hepcidin in response to iron
in vivo, and increases in LIC induce hepatic expression
of BMP6 ligand, whereas increases in Tf sat activate
SMAD1/5/8 phosphorylation downstream of BMP6.
Inhibitory SMAD7 is signiﬁcantly modulated by both
acute and chronic iron administration, mirroring the
overall activation of the SMAD1/5/8 signaling cascade,
and may play a role in feedback inhibition of hepcidin
expression. Hepatic Erk1/2 phosphorylation is not
stimulated by either acute or chronic iron administra-
tion in mice, suggesting that these MAP kinases are
not involved in hepcidin regulation by iron in vivo.
Future studies will be needed to further delineate the
precise molecular mechanisms involved in iron sensing
and BMP6-SMAD pathway activation in hepcidin reg-
ulation and iron homeostasis.
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